29. Sazama K, DeChristopher PJ, Dodd R, et al.: Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. Arch Pathol Lab Med 124:61-70, 2000.
30. Blajchman MA: Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol 114:496-505, 2001.
31. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66:200-205, 1994.
32. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337:1861-1869, 1997.
33. Ogasawara K, Ueki J, Takenaka M, Furihata K: Study on the expression of ABH antigens on platelets. Blood 82:993-999, 1993.
34. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH: Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 96:1574-1581, 2000.
35. Heal JM, Blumberg N, Masel D: An evaluation of cross-matching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 70:23-30, 1987.
36. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host disease. N Engl J Med 323:315-321, 1990.
37. Hayashi H, Nishiuchi T, Tamura H, Takeda K: Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 79:1419-1421, 1993.
38. Williamson LM, Wimperis JZ, Williamson P, et al.: Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study. Blood 83:3028-3035, 1994.
39. Heddle NM, Kelton JG: Febrile nonhemolytic transfusion reactions. In: Popovsky MA (ed.) Transfusion Reactions, 2nd edn. Bethesda, MD: AABB Press; 2001:45-82.
40. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG: A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 33:794-797, 1993.
41. Heddle NM, Klama L, Meyer R, et al.: A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 39:231-238, 1999.
42. Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ: Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 43:1545-1552, 2003.
43. Roback JD, Hillyer CD: Adverse reactions to platelet transfusions. In: Kickler TS, Herman JH (eds.) Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity. Bethesda, MD: AABB Press; 1999:247-285.
44. Gmur J, von Felten A, Osterwalder B, et al.: Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 62:473-479, 1983.
45. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JWN: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trail. Blood 77:201-205, 1991.
46. Freidberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD: Clinical and blood bank factors in the management of platelet refarctoriness and alloimmunization. Blood 81:3428-3434, 1993.
47. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y: Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoi-etic progenitor cell transplantation-a prospective analysis. Transfusion 38:839-847, 1998.
48. Seftel MD, Growe GH, Petraszko T, et al.: Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 103:333-339, 2004.
49. Bowden RA: Transfusion-transmitted cytomegalovirus infection. Hematol Oncol Clin North Am 9:155-166, 1995.
50. Larsson S, Soderberg-Naucler C, Wang FZ, Moller E: Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative health blood donors over time. Transfusion 38:271-278, 1998.
51. Pamphilon DH, Rider JR, Barbara JAJ, Williamson LM: Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion Med 9:115-123, 1999.
52. Roback JD: CMV and blood transfusions. Rev Med Virol 12:211-219, 2002.
53. Ljungman P: Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 125:107-116, 2004.
54. Strauss RG: Leukocyte-reduction to prevent transfusion-transmitted cytomegalovirus infections. Pediatr Transplant 3(suppl 1):19-22, 1999.
55. Ljungman P, Larsson K, Kumlien G, et al.: Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allo-geneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 34:347-350, 2002.
56. Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B: Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 22:575-577, 1998.
57. Narvios AB, Lichtiger B: Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica 86:749-752, 2001.
58. Bowden RA, Slichter SJ, Sayers M, et al.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598-3603, 1995.
59. Blajchman MA, Goldman M, Freedman JJ, Sher GD: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukore-duction. Transfusion Med Rev 15:1-20, 2001.
60. Visconti MR, Pennington J, Garner SF, Allain JP, Williamson LM: Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR. Blood 103:1137-1139, 2004.
61. Nichols WG, Price TH, Corey L, Boeckh M: Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101:4195-4200, 2003.
62. Avery RK, Adal KA, Bolwell BJ: A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 26:763-767, 2000.
63. Meijer E, Boland GJ, Verdonck LF: Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 16:647-657, 2003.
64. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C: Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102:4255-4260, 2003.
65. Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ: Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 74:49-54, 2002.
66. Chakrabarti S, Milligan DW, Brown J, Osman H, Vipond IB, Pamphilon DH, Marks DI: Influence of cytomgalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. Bone Marrow Transplant 33:197-204, 2004.
67. Webb IJ, Anderson KC: Transfusion-associated graft-vs-host disease. In: Popovsky MA (ed.) Transfusion Reactions, 2nd edn. Bethesda, MD: AABB Press; 2001:171-186.
68. Schroeder ML: Transfusion-associated graft-versus-host disease. Br J Haematol 117:275-287, 2002.
69. Przepiorka D, LeParc GF, Stovall MA, Werch J, Lichtiger B. Use of irradiated blood components: practice parameter. Am J Clin Pathol 106:6-11, 1996.
70. Reed W, Fiebig EW, Lee TH, Busch MP: Microchimerism and graft-versus-host disease. In: Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roush KS (eds.) Blood Banking and Transfusion Medicine: Basic Principles & Practice. Philadelphia: Churchill Livingstone; 2003:421-430.
71. Vamvakas EC, Pineda AA: Allergic and anaphylactic reactions. In: Popovsky MA (ed.) Transfusion Reactions, 2nd edn. Bethesda, MD: AABB Press; 2001:83-127.
72. Domen RE, Hoeltge GA: Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 127:316-320, 2003.
73. Yeghen T, Devereux S: Granulocyte transfusion: a review. Vox Sang 81:87-92, 2001.
74. Strauss RG: Granulocyte transfusion therapy. Hematol Oncol Clin North Am 8:1159-1166, 1994.
75. Vamvakas EC, Pineda AA: Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 12:74-81, 1997.
76. Vamvakas EC, Pineda AA: Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 11:1-9, 1996.
77. Hubel K, Dale DC, Engert A, Liles WC: Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 183:321-328, 2001.
78. Vij R, DiPersio JF, Venkatraman P, et al.: Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 101:2067-2069, 2003.
79. Narvios A, Pena E, Han XY, Lichtiger B: Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood 99:390-391, 2002.
80. Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. Transfusion 43:1683-1686, 2003.
81. Stroncek DF, Yau YY, Oblitas J, Leitman SF: Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 41:1037-1044, 2001.
82. Heuft HG, Goudeva L, Sel S, Blasczyk R: Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 l^g/kg) plus dexamethasone versus glycosylated G-CSF (12 ^g/kg) alone. Transfusion 42:928-934, 2002.
83. Heuft HG, Goudeva L, Blasczyk R: A comparative study of adverse reactions occurring after administration of glycoslyated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donors. Ann Hematol 83:279-285, 2004.
84. Bashir S, Cardigan R: Granulocyte concentrates: how can we assess their quality? Transfusion Med 13:245-257, 2003.
85. Volk EE, Domen RE, Smith ML: An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med 123:508-513, 1999.
86. Gleeson C, Spencer D: Blood transfusion and its benefits in palliative care. Palliative Med 9:307-313, 1995.
87. Barnes EA, Bruera E: Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12:424-428, 2002.
88. Weiskopf RB, Kramer JH, Viele M, et al.: Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology 1646-1652, 2000.
89. Cunningham RS: Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 26(suppl 6): 38S-42S, 2003.
90. Halterman JS, Kaczorowski JM, Aligne CA, Auinger P, Szilagyi PG: Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics 107:1381-1386, 2001.
91. Lipschitz D: Medical and functional consequences of anemia in the elderly. J Am Geriatr Soc 51(suppl 3): S10-S13, 2003.
92. Stone P, Kurowska A, Tookman A: Blood transfusion in palliative care. Palliative Med 10:166, 1996.
93. Chiu TY, Hu WY, Cheng SY, Chen CY: Ethical dilemmas in palliative care: a study in Taiwan. J Med Ethics 26:353-357, 2000.
94. Monti M, Castellani L, Berlusconi A, Cunietti E: Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage 12:18-22, 1996.
95. Wachtel TJ, Mor V: The use of transfusion in terminal cancer patients: hospice versus conventional care setting. Transfusion 25:278-279, 1985.
96. Glass E: Different approaches to transfusion practices used in hospice care. OncolNurs Forum 23:117-118, 1996.
97. Singer Y, Shvartzman P: The feasibility and advisability of administering home blood transfusions to the terminally ill patient. J Palliative Care 14:46-48,
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.